Actively Recruiting
AZD0486 1L Therapy for Elderly or Unfit Participants With LBCL
Led by AstraZeneca · Updated on 2026-04-21
420
Participants Needed
62
Research Sites
402 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The purpose of this study is to measure the efficacy and safety of R-mini-CHOP × 2 followed by AZD0486 compared with R-mini-CHOP × 6 in elderly or unfit participants newly diagnosed with LBCL.
CONDITIONS
Official Title
AZD0486 1L Therapy for Elderly or Unfit Participants With LBCL
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Participants are 80 years or older, or aged 65 to 79 and considered unfit per sGA and not candidates for full-dose R-CHOP
- Histologically confirmed previously untreated large B-cell lymphoma (excluding plasmablastic lymphoma and follicular large cell lymphoma)
- FDG-avid and measurable disease according to Lugano and Ann Arbor staging
- Disease stage I bulky (7.5 cm or larger) to stage IV
- ECOG performance status between 0 and 2
- Adequate bone marrow, liver, kidney, and heart function
You will not qualify if you...
- Presence of diseases making participation undesirable or that may affect compliance
- Diagnosis of post-transplant lymphoproliferative disease, plasmablastic lymphoma, Richter's transformation, or prior/concurrent indolent lymphoma
- History of central nervous system involvement or significant CNS medical conditions
- Known history of hemophagocytic lymphohistiocytosis or macrophage activation syndrome
- Active or uncontrolled infection
- Major heart abnormalities
- Prior anti-lymphoma therapy except corticosteroids for symptom control
- Requirement for chronic immunosuppressive therapy for active autoimmune or inflammatory conditions, with some exceptions
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 62 locations
1
Research Site
Melbourne, Australia, 3000
Actively Recruiting
2
Research Site
Nedlands, Australia, 6009
Not Yet Recruiting
3
Research Site
Waratah, Australia, 2298
Not Yet Recruiting
4
Research Site
Antwerp, Belgium, 2030
Not Yet Recruiting
5
Research Site
Brussels, Belgium, 1200
Not Yet Recruiting
6
Research Site
Ghent, Belgium, 9000
Actively Recruiting
7
Research Site
Leuven, Belgium, 3000
Actively Recruiting
8
Research Site
Roeselare, Belgium, 8800
Not Yet Recruiting
9
Research Site
Yvoir, Belgium, 5530
Actively Recruiting
10
Research Site
Porto Alegre, Brazil, 90035-003
Actively Recruiting
11
Research Site
São Paulo, Brazil, 05652000
Actively Recruiting
12
Research Site
Calgary, Alberta, Canada, T2N 5G2
Actively Recruiting
13
Research Site
Ottawa, Ontario, Canada, K1H 8L6
Actively Recruiting
14
Research Site
Beijing, China, 100730
Actively Recruiting
15
Research Site
Changchun, China, 130021
Not Yet Recruiting
16
Research Site
Chengdu, China, 610041
Not Yet Recruiting
17
Research Site
Chongqing, China, 400042
Not Yet Recruiting
18
Research Site
Fuzhou, China, 350011
Not Yet Recruiting
19
Research Site
Guangzhou, China, 510060
Actively Recruiting
20
Research Site
Guangzhou, China, 510280
Not Yet Recruiting
21
Research Site
Haikou, China, 570311
Not Yet Recruiting
22
Research Site
Hefei, China, 230012
Not Yet Recruiting
23
Research Site
Jinan, China, 250117
Actively Recruiting
24
Research Site
Kunming, China, 650101
Not Yet Recruiting
25
Research Site
Nanchang, China, 330000
Not Yet Recruiting
26
Research Site
Nanning, China, 530021
Not Yet Recruiting
27
Research Site
Nantong, China, 226001
Withdrawn
28
Research Site
Shanghai, China, 200003
Actively Recruiting
29
Research Site
Shanghai, China, 20032
Actively Recruiting
30
Research Site
Wuhan, China, 430030
Not Yet Recruiting
31
Research Site
Xiamen, China, 361003
Not Yet Recruiting
32
Research Site
Hong Kong, Hong Kong, 999077
Not Yet Recruiting
33
Research Site
Lai Chi Kok, Hong Kong
Not Yet Recruiting
34
Research Site
Shatin, Hong Kong, 00000
Withdrawn
35
Research Site
Akashi, Japan, 673-8558
Not Yet Recruiting
36
Research Site
Bunkyō City, Japan, 113-8677
Actively Recruiting
37
Research Site
Himeji-shi, Japan, 670-8540
Not Yet Recruiting
38
Research Site
Kōtoku, Japan, 135-8550
Actively Recruiting
39
Research Site
Kumamoto, Japan, 860-8556
Not Yet Recruiting
40
Research Site
Matsumoto-shi, Japan, 399-8701
Not Yet Recruiting
41
Research Site
Matsuyama, Japan, 791-0280
Not Yet Recruiting
42
Research Site
Meguro-ku, Japan, 152-8902
Not Yet Recruiting
43
Research Site
Nagoya, Japan, 460-0001
Not Yet Recruiting
44
Research Site
Osaka, Japan, 543-8555
Not Yet Recruiting
45
Research Site
Osaka, Japan, 545-8586
Actively Recruiting
46
Research Site
Otaki-Shi, Japan, 739-0696
Not Yet Recruiting
47
Research Site
Sunto-gun, Japan, 411-8777
Not Yet Recruiting
48
Research Site
Yamagata, Japan, 990-9585
Actively Recruiting
49
Research Site
Yokohama, Japan, 241-8515
Actively Recruiting
50
Research Site
Kielce, Poland, 25-734
Not Yet Recruiting
51
Research Site
Krakow, Poland, 30-727
Actively Recruiting
52
Research Site
Lodz, Poland, 93-513
Not Yet Recruiting
53
Research Site
Lublin, Poland, 20-090
Not Yet Recruiting
54
Research Site
Wroclaw, Poland, 50-367
Not Yet Recruiting
55
Research Site
Seoul, South Korea, 03080
Actively Recruiting
56
Research Site
Seoul, South Korea, 5505
Actively Recruiting
57
Research Site
Ankara, Turkey (Türkiye), 06620
Actively Recruiting
58
Research Site
Antalya, Turkey (Türkiye), 07025
Actively Recruiting
59
Research Site
Glasgow, Scotland, United Kingdom, G12 0YN
Not Yet Recruiting
60
Research Site
London, United Kingdom, NW1 2PG
Actively Recruiting
61
Research Site
Newcastle upon Tyne, United Kingdom, NE7 7AF
Actively Recruiting
62
Research Site
Nottingham, United Kingdom, NG5 1PB
Not Yet Recruiting
Research Team
A
AstraZeneca Clinical Study Information Center
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
3
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here